Yeti downgraded, Humana upgraded: Wall Street's top analyst calls
RBC upgraded Humana (HUM) to Outperform with a $563 target, citing earnings potential. TD upgraded SPXC to Buy with a $200 target. Phillip upgraded ABNB to Neutral with a $184 target, expecting higher revenue growth. Gordon Haskett upgraded TXRH to Buy with a $220 target. Mizuho double upgraded VIK to Outperform with a $120 target. Goldman downgraded YETI to Neutral with a $41 target. KeyBanc downgraded FMC to Sector Weight.
How this was made

The 30-second read
Why it matters
For traders, the actionable element is the direction and magnitude of rating/PT changes, especially where the article cites concrete negatives (Cogent going-concern warning, Yeti demand softness) or pre-earnings positioning (Viking ahead of Q3).
Market read
This is a sentiment and positioning update across multiple U.S.-listed stocks, with the highest trader focus on downgrades tied to explicit risk signals and large PT cuts.
What to watch
Several theses hinge on assumptions (transitory river levels, domestic demand softness, cost pressure build) that could reverse quickly with new data, making the near-term reaction potentially noisy.
Background
The article is a multi-name analyst note roundup featuring upgrades, downgrades, and coverage initiations with updated price targets and stated theses.
Ticker impact
RBC upgraded Humana to Outperform and raised its price target to $563, citing a Stars turnaround and disciplined medical cost management.
Likely upward pressure as traders price in improved earnings trajectory and higher-conviction analyst expectations.
The article contains a clear rating change plus a materially higher price target tied to specific operational drivers.
TD Cowen upgraded SPX Technologies to Buy and cut its price target to $200, calling current levels a more palatable entry for the same growth profile.
Mixed reaction likely, with upside bias from the upgrade offset by skepticism implied by the PT cut.
The direction is ambiguous because the article pairs an upgrade with a reduced price target.
Phillip Securities upgraded Airbnb to Neutral from Reduce and raised its price target to $184 after the Q3 report, citing higher revenue growth and margins.
Likely modest upward bias as the market digests improved fundamentals assumptions versus the prior downgrade stance.
The article provides a PT increase and specific operating drivers, but the rating is only Neutral.
Gordon Haskett upgraded Texas Roadhouse to Buy and raised its price target to $220, citing accelerating traffic recovery across U.S. regions.
Likely upward pressure as traders align with the view of accelerating traffic recovery.
Clear upgrade plus higher PT anchored to a concrete demand trend.
Mizuho double upgraded Viking Holdings to Outperform and lifted its price target to $120 ahead of the Q3 report, arguing river-level weakness is transitory.
Likely upward pressure as the market anticipates normalization of river levels and improved earnings power.
The thesis is specific, but it is still pre-Q3 and depends on the transitory assumption.
Goldman Sachs downgraded Yeti to Neutral from Buy and cut its price target to $41 after the Q3 report, citing softer domestic demand and rising cost pressures into 2027.
Likely downward pressure as traders reprice risk from weaker domestic demand and cost build.
The article provides a direct downgrade and PT cut with explicit forward-looking drivers.
KeyBanc downgraded FMC to Sector Weight from Overweight, saying crop-chemical demand and pricing look weaker than expected, especially in South America.
Likely downside or underperformance pressure as the market adjusts to weaker demand/pricing assumptions.
No PT is provided, but the downgrade is supported by a specific regional demand/pricing critique.
William Blair downgraded USA Rare Earth to Market Perform from Outperform, noting feedstock shortages as near-term challenges despite potential upside.
Likely limited upside or mild downside as investors focus on feedstock-driven delays.
The article includes a downgrade and a challenge, but lacks a PT and quantification.
Market effects
Broad read-through across managed care, travel/leisure, industrials, and consumer discretionary, but the piece is primarily single-name analyst positioning.
No direct regional macro catalyst; impacts are stock-specific in U.S. trading.
Includes a foreign-listed name (Bilibili) but the drivers cited are company-specific monetization risk rather than global macro.
Counterpoint
Analyst PT changes may be less predictive than upcoming company-specific catalysts (e.g., Viking’s Q3) and near-term earnings revisions, so price may not follow immediately.
Key entities
- companyHumana
Upgraded to Outperform with a raised $563 price target, citing Stars turnaround and medical cost discipline.
- companyYeti
Downgraded to Neutral with a cut $41 price target after Q3, citing softer domestic demand and rising cost pressures.
- companyCogent
Downgraded to Underweight with a cut $4 price target, citing missed Q3 estimates, going-concern warning, and suspended dividend.
